KDR and cholangiocarcinoma: After treatment, the staining intensity of VEGF and VEGFR-1 in RBE+M2 group was still significantly higher than that in RBE group, indicating that Lenvatinib could act on the VEGFR target of cholangiocarcinoma and inhibit its kinase activity, thus blocking tumor angiogenesis.